artesunateamodiaquine

Artesunateamodiaquine is a fixed-dose, oral antimalarial combination used to treat uncomplicated malaria caused by Plasmodium falciparum. It pairs artesunate, a rapidly acting artemisinin derivative, with amodiaquine, a longer-acting 4-aminoquinoline. The combination is part of the artemisinin-based combination therapy (ACT) family.

Pharmacology and regimen: Artesunate rapidly reduces parasite biomass in the bloodstream, while amodiaquine provides sustained antiparasitic activity after artesunate clears much of the infection. The standard course is typically a three-day treatment given once daily, available in fixed-dose tablets or pediatric formulations with dosing by age or weight.

Indications and use: Artesunateamodiaquine is indicated for the treatment of uncomplicated falciparum malaria in areas where the disease is prevalent and chloroquine resistance is common. It is not used for severe malaria, which requires parenteral artesunate or other injectable therapies. The drug is recommended by the World Health Organization and is widely used in many malaria-endemic countries, especially in Africa and parts of Asia.

Safety and adverse effects: Common adverse effects include nausea, vomiting, abdominal pain, and headache. Rare but serious adverse effects reported with amodiaquine include hepatotoxicity and blood dyscrasias; hypersensitivity reactions can occur. It should not be used in individuals with hypersensitivity to artesunate or amodiaquine, and caution is advised in patients with significant liver disease.

Resistance and monitoring: As with other ACTs, inappropriate use or incomplete treatment can promote resistance. Fixed-dose combinations help ensure proper dosing and adherence, but ongoing surveillance of effectiveness and regional resistance patterns remains important.

History and status: Artesunateamodiaquine has become a widely used first-line option for uncomplicated falciparum malaria in many countries and is listed on major national and international treatment guidelines.